Chattem Q2
This article was originally published in The Tan Sheet
Executive Summary
Gross margin based on total revenues reached 72.2%, due in large part to completion of the integration of Selsun Blue manufacturing into Chattem's facilities, CEO Zan Guerry says during June 20 analysts call. For second quarter ended May 31, Chattem recorded an 8% increase in total revenues to $63.6 mil. and a 33% jump in net income to $7.5 mil. Guerry maintained the imminent launch of Icy Hot Back Patch, coupled with the introduction of a new topical analgesic in Q1 2004, should substantially boost sales for the firm (1"The Tan Sheet" March 24, 2003, In Brief). Q2 topical analgesic sales were down year-over-year, Guerry noted, due to success of competitor P&G's ThermaCare heat wraps...
You may also be interested in...
Chattem Icy Hot ads
Q3 launch of Icy Hot Back Patch will be supported with $12 mil. TV, print ad campaign featuring Los Angeles Lakers basketball star Shaquille O'Neal; initiative is expected to spur topical analgesic sales growth in second half, President & COO Alec Taylor says during March 20 analysts call. Chattem has said the line extension could generate annual sales of $6 mil.-$8 mil. (1"The Tan Sheet" Jan. 27, 2003, p. 6). Firm's Q1 revenue jumps 20.7% to $58.4 mil., bolstered by 38% rise in Selsun Blue sales, along with double-digit gains by Icy Hot, pHisoderm, Garlique, Chattanooga, Tenn.-based firm reports. International revenues leap 89% in first quarter, "led by sales of Selsun Blue and the continuing strength of Gold Bond in Canada." Chattem's net income reached $4.6 mil. versus a loss of $6.5 mil. in year-ago period...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.